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Abstract
Background: Few and small studies have described the management of immunomod-
ulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) pa-
tients during coronavirus disease 2019 (COVID- 19) pandemic.
Methods: A national registry, named DA- COVID- 19 and involving 35 Italian dermatol-
ogy units, was established in order to evaluate the impact of COVID- 19 pandemic on 
the management of adult AD patients treated with systemic immunomodulant/im-
munosuppressive medications or phototherapy. Demographic and clinical data were 
obtained at different timepoints by teledermatology during COVID- 19 pandemic, 
when regular visits were not allowed due to sanitary restrictions. Disease severity 
was assessed by both physician- and patient- reported assessment scores evaluating 
itch intensity, sleep disturbances, and AD severity.
Results: A total of 1831 patients were included, with 1580/1831 (86.3%) continu-
ing therapy during pandemic. Most patients were treated with dupilumab (86.1%, 
1576/1831) that was interrupted in only 9.9% (156/1576) of cases, while systemic im-
munosuppressive compounds were more frequently withdrawn. Treatment interrup-
tion was due to decision of the patient, general practitioner, or dermatologist in 39.9% 
(114/286), 5.6% (16/286), and 30.1% (86/286) of cases, respectively. Fear of increased 
susceptibility to SARS- CoV- 2 infection (24.8%, 71/286) was one of the main causes of 
interruption. Sixteen patients (0.9%) resulted positive to SARS- CoV- 2 infection; 3 of 
them (0.2%) were hospitalized but no cases of COVID- related death occurred.
Conclusions: Most AD patients continued systemic treatments during COVID pan-
demic and lockdown period, without high impact on disease control, particularly 
dupilumab- treated patients.
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1  |  INTRODUC TION
COVID- 19, caused by SARS- CoV- 2 infection, has spread rapidly world-
wide becoming pandemic, as defined by the World Health Organization 
on 18th March 2020.1 Most patients exhibit mild- to- moderate symp-
toms and recover without sequelae, though hospitalization, generally 
due to pneumonia, and more severe respiratory involvement such as 
acute respiratory distress syndrome, septic shock, and/or multiple 
organ failure, associated with high mortality, may occur.1
Italy has faced the first wave of SARS- CoV- 2 infection out of 
China before the rapid worldwide pandemic spreading. To face the 
virus spreading, a nationwide lockdown period (phase I) limiting all 
kind of activities including healthcare services was decided on March 
10th and lasted until May 4th, when a phase II was planned with a 
gradual re- opening of hospital dermatology services. During these 
two initial phases, medical visits were restricted to urgent cases, and 
the use of teledermatology was implemented in many dermatological 
services. On 15th June 2020, a phase III was established recovering 
almost all activities with sanitary restrictions, and healthcare services 
were restored based on the decision of local sanitary authorities.
Thereby, COVID- 19 pandemic led to the sudden need of increasing 
the use of web and phone consulting, and defining practical guidelines 
for the management of immune- mediated dermatologic conditions, 
such as AD that in moderate- to- severe cases are commonly treated 
with systemic immunomodulant/immunosuppressive compounds or 
phototherapy. The effect of immunomodulant/immunosuppressive 
compounds on the clinical course of COVID- 19 is currently unclear, 
and there is concern of an increased risk of infection in AD patients 
treated with systemic compounds, though the continuation of ther-
apy during pandemic was recommended by national and international 
scientific societies.2- 7 Nevertheless, immunomodulant/immunosup-
pressive agents, such as methotrexate, mycophenolate, azathioprine, 
and cyclosporine, were suggested to be tapered to the lowest effec-
tive dose, likely avoiding disease flare, and to consider drug discon-
tinuation in patients when viral symptoms are present.2,5 Similarly, 
caution was recommended in prescribing systemic corticosteroids 
given their broad immunosuppressive effects.2,5 Furthermore, some 
authors recommended halting office- based phototherapy to minimize 
potential exposure to SARS- CoV- 2 virus and instead encourage ex-
posure of affected areas to natural sunlight, bleach baths, and wet 
wraps.5 However, current recommendations are based on limited 
knowledge regarding the risk of systemic immunomodulant/immu-
nosuppressive compound use, and few data related to AD patients 
treated during COVID- 19 pandemic.
We designed a national registry, the DA- COVID- 19 registry, 
aimed to evaluate the impact of the pandemic on the therapeu-
tic management and clinical course of AD in patients treated with 
any systemic immunomodulant/immunosuppressive compound or 
phototherapy. This observational study analyzed clinical and de-
mographic characteristics of moderate- to- severe AD patients, who 
were managed with telemedicine and eventually by regular ambula-
tory visits during the COVID- 19 pandemic.
2  |  METHODS
This cross- sectional, multicentric, observational study was con-
ducted in 35 Italian centers. This registry, which was aimed to 
collect data on moderate– severe AD patients treated with sys-
temic agents and/or phototherapy during COVID- 19 outbreak, has 
G R A P H I C A L  A B S T R A C T
Among 1831 studied AD patients, 86.1% were treated with dupilumab. Patients continuing therapy experienced a marked reduction of 
disease severity during pandemic. The causes of treatment interruption included: fear of increased susceptibility to SARS- CoV- 2 infection 
(24.8%), occurrence of comorbidities (5.9%), age above 60 years (5.2%), SARS- CoV- 2 infection (2.8%), close contact with SARS- CoV- 2- 
positive subject (2.4%), other reasons, for example, inability to maintain drug supply, non- medical/unspecified causes (58.7%).
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been promoted by the Italian Society of Dermatology (SIDeMaST) 
and approved by the national ethical committee for COVID- 19- 
related studies (Istituto Nazionale per le MalattieInfettive Lazzaro 
Spallanzani I.R.C.C.S.). The study period included the three phases 
of first- wave COVID- 19 pandemic in Italy (Figure S1).
Adult patients (aged ≥18 years) affected by moderate- to- severe 
AD, treated with systemic immunosuppressive/immunomodulant 
compounds or phototherapy, were included in the DA- COVID- 19 
registry if face- to- face evaluation or remote visit (via telephone or 
web consulting) were performed between 10th March and 30th 
April 2020. By April 30th, data have been collected monthly, there-
after, on an ad hoc database. Data were collected at 3 different time-
points: April 30th (Timepoint 1), May 30th (Timepoint 2), and June 
30th (Timepoint 3) (Figure S1). Subjects who signed the informed 
consent were included in this study. Baseline data included age, gen-
der, occupation, atopic comorbidities, smoking habits (smoker, for-
mer smoker, or non- smoker), and disease severity.
2.1  |  Disease severity assessment
Disease severity was assessed by EASI score at timepoint 1 (either 
assessed during face- to- face visit or the last recorded EASI score in 
patient's file) and at timepoint 3, being performed if dermatology 
units restored their regular outpatient clinical activity. At timepoint 
2, due to sanitary restriction, no EASI score was reported. In addi-
tion, patient- reported evaluations included: 0- 10 NRS for pruritus 
intensity (itch NRS), sleep disturbances/sleeplessness by a 0- 10 NRS 
scale (sleep NRS), self- evaluated AD severity by a 0- 10 NRS scale 
(AD- NRS), self- evaluation of patient's AD clinical course (patient 
perception of “AD status,” defined as stable/no flaring, improved, or 
worsened, during the observation period), and ongoing treatment. 
Details about treatment interruption or suspension were recorded. 
Data on SARS- CoV- 2 swab testing, hospitalization, clinical out-
comes of COVID- 19 disease, and quarantine due to close contact to 
COVID- 9 patients were also collected.
2.2  |  Statistical analysis
Patients were analyzed according to their ongoing therapy to identify 
possible differences in any of the demographic or clinical variables 
collected. Frequency and percentages were the descriptive analyses 
performed on the categorical variables. Continuous variables were 
summarized as means ±standard deviation. For categorical variables, 
differences between groups were evaluated using chi- squared test 
or Fisher's exact test (if more than 20% of the cells in a contingency 
table have expected counts less than 5). For quantitative variables, 
the Shapiro- Wilk test was performed in order to test the normality 
of data. If the p- value was less than or equal to 0.05 (non- normality), 
the comparison between groups was performed by means of the 
non- parametric Wilcoxon rank- sum test. Otherwise, the compari-
son was performed using the t- test. Moreover, comparison between 
timepoint 1 value and the other timepoints was performed using 
the paired t- test (or the Wilcoxon signed- rank test in the case of 
non- normal data). Finally, an ANOVA test (or Kruskal– Wallis test in 
the case of non- normal data) was performed to compare the means 
in case of more than 2 groups. Differences were considered statisti-
cally different if P values resulted <0.05. Analyses were performed 
using software SAS 9.4 version (SAS, NC, USA).
3  |  RESULTS
The DA- COVID registry included 1831 patients with moderate- to- 
severe AD presenting demographic and clinical characteristics as il-
lustrated in Table 1. Overall, 142/1831 (7.7%) patients were lost to 
follow- up throughout the observation period.
3.1  |  SARS- CoV- 2 infection in the study population
Fifty- nine of 1831 (3.2%) AD patients performed in total 79 SARS- 
CoV- 2 nasal– throat swab tests; 16/1831 (0.9%) had a confirmed 
diagnosis of SARS- CoV- 2 infection; and 3 (0.2%) were hospital-
ized. No cases of death from COVID- related disease occurred in 
our study population throughout the whole observation period. 
The 16 SARS- CoV- 2- positive patients had a mean age of 45.1 years 
(±16.4); 9 were females (56.3%), presenting rhinitis as the most 
common atopic comorbidity 10/16 (62.5%) (Table 2). AD severity 
was in line with the overall patient population (data not shown). 
Comparing AD patients positive to SARS- CoV- 2 nasal– throat swab 
testing with those who resulted negative, no significant differ-
ence in mean baseline EASI score was found (7.744 ± 2.062 for 
SARS- CoV- 2- positive patients vs 5.830 ± 0.9865 for SARS- CoV- 
2- negative patients, P = 0.3577). Fifteen of 16 (93.8%) patients 
were undergoing dupilumab therapy when SARS- CoV- 2 occurred 
(Table 2). Dupilumab was mostly used in monotherapy (80%, 13/15) 
while in 20.0% (3/15) of patients was combined with systemic cor-
ticosteroids and/or methotrexate. Half of SARS- CoV- 2- positive pa-
tients discontinued treatment. SARS- CoV- 2- positive patients who 
continued treatment were all undergoing dupilumab therapy and 
exhibited a significant reduction of mean EASI score from timepoint 
1 to timepoint 3 (7.7 ± 2.1 at timepoint 1 vs 2.3 ± 1.3 at timepoint 3, 
P = 0.0468). Similarly, EASI score significantly decreased in patients 
discontinuing therapy overtime (timepoint 1: 9.9 ± 9.5 vs time-
point 3: 0.4 ± 0.52, P = 0.013). Neither dupilumab- related adverse 
events (i.e., injection site reaction or conjunctivitis) nor COVID- 19 
complication or worsening was reported in those cases continuing 
therapy. Because of close contact with COVID- 19 cases or high- risk 
conditions for SARS- CoV- 2 infection, 3.2% (58/1831) of patients 
underwent quarantine.
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TA B L E  1  Clinical and demographic characteristics of patients included in the DA- COVID- 19 registry, dissecting patients who continued 





Number of patients (%) 1580 (86.3%) 251 (13.7%) 1831
Age [years] (±SD) 42.3 (17.2) 41.5 (18.2) 42.2 (17.4)
Gender [Males] n pts (%) 867 (54.9%) 132 (52.6%) 999 (54.6%)
Smoking
No 1087 (68.9%) 172 (68.5%) 1259 (68.8%)
Yes 365 (23.1%) 59 (23.5%) 424 (23.2%)
Former smoker 126 (8.0%) 20 (8.0%) 146 (8.0%)
Concomitant atopic conditions
Rhinitis 741 (46.9%) 118 (47.0%) 859 (46.9%)
Conjunctivitis 563 (35.7%) 77 (30.8%) 640 (35.0%)
Asthma 498 (31.5%) 79 (31.5%) 577 (31.5%)
Total of treatment course interruptions — 286 286
Timepoint 1 (lockdown phase 1)
Stopped Therapy
By patient decision — 92/286 (32.2%) 92
By dermatologist — 41/286 (14.3%) 41
By general practitioner — 12/286 (4.2%) 12
Unknown — 47/286 (16.4%) 141
Reason for stopping therapy
Any reason 192/286 (67.1%)
Fear of SARS- CoV−2 infection — 62/286 (21.7) 62
SARS- CoV−2 infection — 6/286 (2.1%) 6
Contact with SARS- CoV−2+ subject — 7/286 (2.4%) 7
Comorbidity — 10/286 (3.5%) 10
Age >60 years old — 6/286 (2.1%) 6
Other (i.e., drug supply, no mobility, etc) — 101/286 (35.3%) 101
Timepoint 2 (phase 2)
Stopped Therapy
By patient decision — 14/286 (4.9%) 14
By dermatologist — 22/286 (8.5%) 22
By general practitioner — 3/286 (6.0%) 3
Unknown — 9/286 (1.0%) 9
Reason for stopping therapy
Any reason — 48/286 (16.8%) 48
Fear of SARS- CoV−2 infection — 6/286 (2.1%) 6
SARS- CoV−2 infection — 2/286 (0.7%) 2
Contact with SARS- CoV−2+ subject — — - 
Comorbidity — 5/286 (1.7%) 5
Age >60 years old — 3/286 (1%) 3
Other (i.e., drug supply, no mobility) — 32/286 (11.2%) 32
Timepoint 3 (phase 3)
Stopped Therapy
By patient decision — 8/286 (2.8%) 8
By dermatologist — 23/286 (8.0%) 23
By general practitioner — 1/286 (2.1%) 1
(Continues)
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3.2  |  Characterization of treatment path in the 
study population
Overall, 63.2% (1157/1831) and 36.8% (674/1831) of patients were 
treated in monotherapy or with two or more systemic agents, re-
spectively. Most patients (55.3%, 1013/1576) were treated with 
dupilumab monotherapy, while in 30.8% (563/1831) dupilumab was 
associated with other systemic agents or phototherapy (Figure S2). 
Immunosuppressive systemic compounds were used as either 
monotherapy or combination therapy as showed in Table 3. More 
frequently, antihistamines (76.2%, 429/563), oral corticosteroids 
(19.2%, 108/563), and cyclosporine (12.6%, 71/563) were associated 
with dupilumab as combination therapy. A small percentage of AD pa-
tients (13.9%, 255/1831) was exclusively treated with conventional 
systemic therapies, including phototherapy (Figure S2). Notably, pa-
tients treated with dupilumab combined with other systemic thera-
pies had significantly higher rates of concomitant atopic conditions 
compared to patients treated with dupilumab monotherapy or sys-
temic immunosuppressive compounds (P < 0.001; Table S1). Across 
treatment subgroups, no worsening of atopic comorbid conditions 
was reported as adverse event.
In a small proportion of patients (53/1831, 2.9%), systemic ther-
apy was modified including a total of 66 therapy modifications con-





Unknown — 14/286 (30.4%) 14
Reason for stopping therapy
Any reason — 46/286 (16.1%) 46
Fear of SARS- CoV−2 infection — 3/286 (1.0%) 3
SARS- CoV−2 infection — — - 
Contact with SARS- CoV−2+ subject — — - 
Comorbidity — 2/286 (0.7%) 2
Age >60 years old — 6/286 (2.1%) 6
Other (i.e., drug supply, no mobility) — 35/286 (12.2%) 35
Missing data about decision of treatment 
interruption
70/286 (24.5%)
Number of patients lost to follow- up (%) 142/1831 (7.7%)







Number of patients 8 8 16
Sex M/F (%/%) 2/6 (25%/75%) 5/3 (62.5%/37.5%) 7/9 (43.8%/56.2%)
Age (±SD) 47.9 (±17.7) 42.3 (±15.7) 45.1 (±16.4)
Rhinitis 6 (75.0%) 4 (50.0%) 10 (62.5%)
Conjunctivitis 4 (50.0%) 4 (50.0%) 8 (50.0%)
Asthma 3 (37.5%) 4 (50%) 7 (43.8%)




8 (100.0%) 7 (87.5%) 15 (93.8%)
Antihistamines 0 3 (37.5%) 3 (18.8%)
Corticosteroids n. 
patients (%)
0 2 (25.0%) 2 (12.5%)
Phototherapy n. 
patients (%)
0 2 (25.0%) 2 (12.5%)
Methotrexate n. 
patients (%)
1 (12.5%) 0 1 (6.3%)
Data are reported as means (± standard deviation) or numbers (%).
TA B L E  2  Clinical and demographic data 
of COVID- 19+ AD patients
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dose) or lengthening drug administration interval, at least once. 
The addition to or substitution of the systemic therapy with topical 
agents, homeopathy, or other non- systemic therapies (i.e., sun expo-
sure) occurred in 937 cases.
In total, 251 patients discontinued treatment. One hundred ten 
of 251 patients (43.8%) temporarily suspended therapy that was re-
started during the whole observation period, whereas 141 patients 
continued to manage AD with topical therapies, emollients, home-
opathy, or other non- systemic therapies.
3.3  |  Different management of immunosuppressive 
systemic compounds compared to dupilumab
The majority of patients (86.3%, 1580/1831) continued therapy, 
whereas 13.7% of patients (251/1831) withdrew systemic therapy 
at least once, with a mean duration of treatment interruption of 
56.5 days (±27.2), and a total number of therapeutic course inter-
ruptions of 286. Most of treatment interruptions was recorded at 
timepoint 1 (67.1%, 192/286), whereas in 16.8% (48/286) and 16.2% 
(46/286) of cases, therapy was withdrawn at timepoint 2 and 3, re-
spectively. Treatment interruptions occurred with similar distribution 
across the three cohorts of patients treated with systemic immuno-
suppressive compounds (36.4% of cases with at least one treatment 
interruption), dupilumab monotherapy (32.9%), or dupilumab com-
bined with other systemic therapies (30.7%). Nevertheless, consid-
ering the rate of treatment interruption for each drug, dupilumab 
was interrupted in only 9.9% (156/1576) of cases, whereas cyclo-
sporine, antihistamines, oral corticosteroids, phototherapy, and 
methotrexate were interrupted in 40.9% (52/127), 39.9% (190/476), 
23.4% (34/145), 74.1% (60/81), and 23.5% (12/51) of cases, respec-
tively (Table 3).
In 39.9% (114/286) of cases, treatment interruption was due to 
patient decision, while in 5.6% (16/286) and 30.1% (86/286) of cases, 
treatment interruption was suggested by the general practitioner 
and by the dermatologist, respectively. In particular, the interrup-
tion of systemic immunosuppressive compounds was more fre-
quently suggested by the dermatologist (40.4%, 42/104), whereas 
dupilumab monotherapy or dupilumab combined with other sys-
temic therapies were mostly interrupted because of patient deci-
sion (53.2% [50/94]; 50% [44/88], respectively) (Table S1). In details, 
one or more reasons led to the decision of stopping therapy: (i) the 
inability to maintain drug supply, other non- medical or unspecified 
causes (58.7%, 168/286 cases); (ii) the occurrence of concomitant 
comorbid conditions (5.9%, 17/286 cases); (iii) age, over 60 years 
old (5.2%, 15/286 cases); (iv) close contact with SARS- CoV- 2+ sub-
ject (2.4%, 7 /286); (v) SARS- CoV- 2 infection (2.8%, 8/286); and (vi) 
fear of increased susceptibility to SARS- CoV- 2 infection (24.8%, 
71/286). Fear of increased susceptibility to SARS- CoV- 2 infection 
caused treatment interruption in 23.4%, 23.9%, and 26.9% of pa-
tients treated with dupilumab monotherapy, dupilumab combined 
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3.4  |  Different AD clinical courses in patients 
withdrawing treatment compared to patients 
continuing therapy
At timepoint 1 (lockdown phase), disease severity assessment of 
the whole patient population showed: mean EASI score of 6.8 ± 7.7, 
itch NRS of 2.6 ± 2.2, sleep NRS of 1.7 ± 2.1, and self- assessment 
of AD severity, AD- NRS of 2.5 ± 2.1 (Table 4). During the study pe-
riod, patients experienced a significant reduction of mean itch NRS, 
mean sleep NRS, and mean AD- NRS scores, achieving lower mean 
scores at timepoint 3, compared to timepoint 1 (Tables S2 and S3). 
This improvement reflected the significant decrease of mean EASI 
score at timepoint 3 (3.4 ± 4.4) compared to timepoint 1 (6.8 ± 7.7, 
P < 0.0001). Reduction of mean EASI score was observed in both 
patients continuing treatment and patients interrupting systemic 
therapy, though at different extent (Table 4). Indeed, mean EASI 
score changed in the cohort of patients continuing treatment over 
time (6.6 ± 7.8 at timepoint 1 vs 2.8 ± 3.4 at timepoint 3), obtaining 
TA B L E  4  Disease severity assessed at different timepoints related to therapy continuation or discontinuation. Both patient- assessed 
severity measurements— itch NRS score, sleep NRS score, AD- NRS score, course of disease (improved, stable, worsened)— and physician- 
assessed severity measure (EASI score) were performed in all patient population, in the subcohort of patients treated continuously, and in 
the subcohort of patients who discontinued treatment
Patients continuing 
treatment (n. pts: 1580)
Patients discontinuing 
treatment (n. pts: 251)
Total population 
(n. pts: 1831)
Timepoint 1 (lockdown- phase 1)
Mean EASI score (±SD)ç  6.6 (7.8)#  8.2 (7.5)#  6.8 (7.7)
Mean itch NRS score (±SD) 2.4 (2.1) 3.7 (2.3) 2.6 (2.2)
Mean sleep NRS score (±SD) 1.6 (2.0) 2.7 (2.4) 1.7 (2.1)
AD- NRS score (±SD) 2.3 (2.0) 3.5 (2.2) 2.5 (2.1)
Self- reported AD status§ 
Improved n. pts (%) 454 (28.8%) 39 (15.5%) 493 (27.0%)
Stable n. pts (%) 961 (60.9%) 122 (48.6%) 1083 (59.2%)
Worsened n. pts (%) 162 (10.3%) 90 (35.9%) 252 (13.8%)
Timepoint 2 (phase 2)
Mean itch NRS score (±SD) 2.4 (2.1) 3.7 (2.3) 2.6 (2.2)
Mean sleep NRS score (±SD) 1.5 (1.8) 2.8 (2.8) 1.6 (2.0)
AD- NRS score (±SD) 2.1 (1.9) 3.7 (2.6) 2.3 (2.1)
Self- reported AD status§ 
Improved n. pts (%) 417 (27.2%) 53 (22.1%) 470 (26.5%)
Stable n. pts (%) 980 (63.8%) 102 (42.5%) 1082 (61.0%)
Worsened n. pts (%) 138 (9.0%) 85 (35.4%) 223 (12.6%)
Timepoint 3 (phase 3)
Mean EASI score (±SD)ç  2.8 (3.4) 7.3 (7.7) 3.4 (4.4)
Mean itch NRS score (±SD) 3.3 (2.6) 3.3 (2.6) 2.2 (2.1)
Mean sleep NRS score (±SD) 1.2 (1.7) 2.2 (2.4) 1.3 (1.9)
AD- NRS score (±SD) 1.9 (1.9) 3.0 (2.4) 2.1 (2.0)
Self- reported AD status§ 
Improved n. pts (%) 442 (30.2%) 69 (30.7%) 511 (30.3%)
Stable n. pts (%) 921 (62.9%) 113 (50.2%) 1034 (61.2%)
Worsened n. pts (%) 101 (6.9%) 43 (19.1%) 144 (8.5%)
Change in EASI score from timepoint 1 to timepoint 3 −2.8 (7.1) −0.2 (7.7) −2.5 (7.2)*
Change in itch NRS from timepoint 1 to timepoint 3 −0.3 (2.0) −0.2 (2.7) −0.3 (2.1)*
Change in sleep NRS from timepoint 1 to timepoint 3 −0.3 (1.9) −0.3 (2.8) −0.3 (2.0)*
Change in AD- NRS from timepoint 1 to timepoint 3 −0.4 (1.8) −0.3 (2.4) −0.4 (1.9)*
Abbreviations: AD, atopic dermatitis; EASI: Eczema Area and Severity Index; NRS: Numeric Rating Scale; pts: patients; SD: standard deviation.
#P < 0.001, Wilcoxon rank- sum test was used to compare the 2 patient subcohorts at timepoint 1. 
§P < 0.001, chi- squared test was used for statistical analysis. 
çMean EASI score was calculated on 1831 and 746 patients at timepoint 1 and 3, respectively. 
*P < 0.0001, paired s test was used to compare T1 vs T3 in the total population. 
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a 10- fold higher reduction compared to the cohort of patients 
withdrawing treatment (8.2 ± 7.5 at timepoint 1 vs 7.3 ± 7.7 at time-
point 3).
Self- assessment of itch, sleep, and disease severity did not reveal 
any marked difference between the two patient subcohorts in terms 
of score reduction (Table 4).
At timepoint 1, AD improvement was experienced by a higher 
percentage of patients continuing therapy compared to patients dis-
continuing treatment (28.8% vs 15.5%, P < 0.001). Stable AD was re-
ported by 60.9% of patients continuing therapy compared to 48.6% 
of patients interrupting therapy. On the contrary, an increased num-
ber of patients discontinuing therapy described worsening of disease 
compared to patients continuing therapy (35.9% vs 10.3%). Similarly, 
AD status perceived by patients continuing or interrupting therapy 
was significantly different at the following timepoints (P < 0.001; 
Table 4). Comparing patients treated with dupilumab monotherapy, 
dupilumab combined with other systemic therapies, and immuno-
suppressive systemic compounds, a reduction of disease severity 
(EASI score, and NRS scores) was detected at timepoint 3 vs time-
point 1, as well as a significantly different AD status across the three 
patient cohorts at each time point (P < 0.0001, Table S2). Patients 
treated with dupilumab monotherapy showed lower disease activity 
at timepoint 1, with a mean EASI score significantly lower compared 
to the other patients (P < 0.001), and this improvement was sus-
tained thereafter (Table S2).
4  |  DISCUSSION
This observational study included a large population of patients 
(1831 adult subjects) affected by moderate- to- severe AD and 
treated with systemic therapies or phototherapy, and managed 
during the COVID- 19 pandemic in Italy. The participating centers 
(n = 35) were highly representative of the different incidence dis-
tribution of SARS- CoV- 2 infection nationwide, having 15, 10, and 
10 centers located in Northern, Central, and Southern Italy, respec-
tively.8 During the observation period, a total number of 240,578 
SARS- CoV2- positive cases were registered, with a cumulative num-
ber of 190,248 recovered cases and 34,767 deaths.8 In details, na-
tional incidence at timepoint 1, 2, and 3 was 0.71% (95% CI: 0.4– 1.2), 
0.27% (95% CI: 0.1 – 0.64), and 0.11% (95% CI: 0.0 – 0.4), in line 
with the infection rate observed in our AD population (timepoint 1: 
0.71%; timepoint 2: 0.16%; timepoint 3: 0%). In our study population, 
less than 1% of patients (16/1831) resulted positive to SARS- CoV- 2, 
with only three patients who required hospitalization, though swab 
testing was not massively performed throughout the study period. 
During this critical sanitary emergency, clinical activity in dermatol-
ogy clinics was markedly limited, and teledermatology (web- and 
phone- counseling) was extremely useful for reducing patient access 
to hospital. This modality was well accepted by AD patients who 
continued to have access to dermatologist consultation, guarantee-
ing support and treatment continuation in the majority of cases. 
Indeed, a relatively low number of patients were lost to follow- up 
(7.7%). As suggested by both national and international scientific 
societies, most patients were recommended to continue their cur-
rent treatment during COVID- 19 pandemic.2 About 86% of patients 
continued treatment, including 8 patients who resulted positive to 
SARS- CoV- 2 infection, albeit common recommendations suggested 
to withdraw therapy. Notably, 85% of patients included in this study 
were treated with dupilumab, mostly prescribed as monotherapy.
Considering disease severity assessment, patients undergoing 
dupilumab monotherapy showed lower disease activity suggesting 
a better control of AD compared to patients treated with systemic 
immunosuppressive compounds or dupilumab combined with other 
systemic therapies. Albeit dupilumab- treated patient cohort exhib-
ited lower disease severity at baseline and throughout the study 
period compared to the other treatments, superiority of dupilumab 
during COVID pandemic cannot be suggested based on this data re-
ferring to a limited time frame and heterogeneous baseline patients’ 
characteristics across different treatment groups. The therapeutic 
regimen combining dupilumab with other systemic agents occurred 
in a cohort of patients with significantly higher prevalence of atopic 
disorders who may require this combined approach as likely they rep-
resent a high- need patient population. Nevertheless, no worsening 
of atopic comorbid conditions was reported. Response to treatment 
in these patients resulted similar to patients treated with dupilumab 
monotherapy or systemic immunosuppressive compounds. This lat-
ter class of agents was supposed to have an unfavorable safety pro-
file compared to biologics but no warning signal was detected in our 
study. Dupilumab does not impair the immune compartments impli-
cated in host defense against viral infections and thus may be consid-
ered a safer therapeutic choice for AD.9- 12 In dupilumab clinical trials, 
rates of general infections, upper respiratory tract infections, and 
nasopharyngitis resulted similar to placebo, and, in particular, viral in-
fections, were not reported as meaningful adverse event.7,13In terms 
of effectiveness, dupilumab therapy obtained a satisfactory control 
of the disease and consistently with the other systemic compounds, 
treatment interruption did not cause a rapid and relevant worsening 
of the disease, as highlighted by the decrease of both patient- assessed 
severity scores and EASI score in patients discontinuing therapy. This 
finding is in line with a recent study reporting maintenance of EASI- 
75 response in 30.4% of high- responding patients treated with dupi-
lumab, after rerandomization to placebo.14 However, the reduction of 
disease severity in patients discontinuing therapy was not associated 
with a positive patient perception of AD status: a higher percentage 
of patients withdrawing therapy evaluated their AD status as wors-
ened. Likely, therapy continuation, compared to an intermittent or 
discontinued therapeutic regimen, might positively impact on patient 
perception of both disease control and severity.
Dupilumab was interrupted in a small percentage of patients, 
conversely to cyclosporine and oral corticosteroids. In addition, pho-
totherapy was interrupted in most cases (about 74%) due to the lack 
of accessibility to phototherapy services during phase I (lockdown). 
Dupilumab interruption was mainly based on patient decision, and 
the main cause of interruption was represented by non- medical 
reasons (lack of drug supply). Fear of having an increased risk of 
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COVID- 19 disease determined treatment interruption in 25% of pa-
tients withdrawing therapy, similarly to recent findings observed in 
psoriasis patients.15 Another study confirmed that patients affected 
by either psoriasis (233 patients) or AD (68 patients) who felt unsafe 
about their immunomodulatory treatment were more concerned 
about having SARS- CoV- 2 infection and more likely discontinued 
therapy during pandemic (overall treatment interruption: 7.3%).16 
In particular, AD patients with asthma were more concerned about 
being at risk of COVID- 19 disease because of AD and its treatment.16
The strength of our study is the large AD population treated with 
systemic therapies who was observed longitudinally, during the national 
lockdown period (phase I) and the following phase of partial and gradual 
re- opening of healthcare services (phase II and III) that were planned in 
order to face COVID- 19 outbreak. In particular, this study provided evi-
dence that continuation of immunomodulant/immunosuppressive ther-
apies during COVID- 19 pandemic can be considered safe and effective 
in controlling AD. This finding strengthens the recommendations issued 
by national and international scientific societies at the beginning of the 
COVID- 19 outbreak that are based on experts’ opinion.2- 5 Notably, this 
study also suggested that drug interruption did not cause AD flares, as 
treatment response was maintained in the short term.
However, some limitations related to the data collection, man-
agement, and disease severity evaluation via web or phone counsel-
ing should be considered as most of the assessment tools used were 
patient- reported and only a minor percentage of patients could be eval-
uated by regular visits during phase 3. Detailed information about atopic 
comorbid conditions, SARS- CoV- 2 serology testing were not collected. 
In addition, most patients were undergoing dupilumab therapy with a 
satisfactory control of the disease, particularly with dupilumab mono-
therapy (mean T1 EASI score significantly lower than other treatment 
groups), and this could represent a selection bias of the study popula-
tion likely related to the relatively higher number of dupilumab- treated 
patients managed in a dedicated AD outpatient clinic.
Data collection related to AD patients treated with systemic 
compounds and/or phototherapy during COVID- 19 pandemic is 
continuing by the DA- COVID- 19 registry, willing to delineate the 
infectious risk related to the use of each immunomodulant/immu-
nosuppressant agent in AD patient population and to better char-
acterize COVID- 19 outcomes in patients with AD, as internationally 
promoted by the SECURE- AD registry.17
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